Binds Enzyme Patents (Class 530/388.26)
-
Patent number: 7601816Abstract: The invention relates to the isolation of novel cyclooxygenase type 1 (COX-1) variant enzymes. More specifically, the invention relates to the identification of cyclooxygenase transcripts harboring inton 1, or fragment thereof, of cyclooxygenase 1. The invention further relates to the diagnosis of aberrant cyclooxygenase type 1 variant gene or gene product; the identification, production, and use of compounds which modulate cyclooxygenase type 1 variant gene expression or the activity of the cyclooxygenase type 1 variant gene product including but not limited to nucleic acid encoding cyclooxygenase type 1 variants and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules; and pharmaceutical formulations and routes of administration for such compounds.Type: GrantFiled: November 17, 2006Date of Patent: October 13, 2009Assignee: Brigham Young UniversityInventors: Daniel Simmons, N. Vishvanath Chandrasekharan
-
Patent number: 7579447Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.Type: GrantFiled: March 7, 2006Date of Patent: August 25, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
-
Patent number: 7579002Abstract: A method for improving animal body weight uniformity or for increasing animal carcass yield is disclosed. The method involves administering an agent to one or a group of animals wherein the agent can reduce bioavailability of a prostaglandin or leukotriene lipid precursor. In a preferred embodiment, the agent employed is an anti-PLA2 antibody.Type: GrantFiled: January 21, 2004Date of Patent: August 25, 2009Assignees: Wisconsin Alumni Research Foundation, Michigan State UniversityInventors: Mark E. Cook, Mingder Yang, Kevin Roberson
-
Publication number: 20090208510Abstract: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.Type: ApplicationFiled: March 11, 2009Publication date: August 20, 2009Applicant: Yeda Research And Development Co. Ltd.Inventors: Irit Sagi, Tamar Danon
-
Publication number: 20090202526Abstract: The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.Type: ApplicationFiled: December 23, 2004Publication date: August 13, 2009Inventor: Jaume Pons
-
Publication number: 20090203040Abstract: Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.Type: ApplicationFiled: June 27, 2008Publication date: August 13, 2009Inventors: Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
-
Patent number: 7569669Abstract: The invention provides a novel calcium-independent cytosolic phospholipase A2/B enzyme, polynucleotides encoding such enzyme and methods for screening unknown compounds for anti-inflammatory activity mediated by the arachidonic acid cascade.Type: GrantFiled: July 6, 2006Date of Patent: August 4, 2009Assignee: Genetics Institute, LLCInventors: Simon Jones, Jin Tang
-
Publication number: 20090180952Abstract: Antibodies or other ligands specific for the binary uPA-uPAR complexes, for ternary complexes comprising uPA-uPAR and for complexes of uPAR and proteins other than uPA such as integrins inhibit the interaction of uPA and uPAR with additional molecules with which the complexed interact. Such antibodies or other ligands are used in diagnostic and therapeutic methods, particularly against cancer.Type: ApplicationFiled: May 25, 2005Publication date: July 16, 2009Applicant: MELEXIS NVInventors: Graham C. Parry, Andrew P. Mazar
-
Patent number: 7550569Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to GMAD. Such antibodies have uses, for example, in the prevention and treatment of both insulin- and non insulin-dependent diabetes mellitus (i.e. Type I and Type II diabetes) and other related disorders. The invention also relates to nucleic acid molecules encoding anti-GMAD antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially diabetes and other related disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to GMAD.Type: GrantFiled: September 8, 2004Date of Patent: June 23, 2009Assignee: Human Genome Science, Inc.Inventors: Kevin P. Baker, Vivian R. Albert, Partha Chowdhury
-
Publication number: 20090148866Abstract: The present disclosure relates to isolated antibodies that can be used in an assay to determine the concentration levels of myeloperoxidase (MPO) in a test sample. Additionally, the present disclosure also relates to the use of improved test sample handling methods in assays in order to preserve the original MPO levels in the test sample.Type: ApplicationFiled: May 16, 2008Publication date: June 11, 2009Applicant: Abbott LaboratoriesInventors: Saul A. Datwyler, David J. Hawksworth, Stephen C. Hsu, Matthew S. Matias, David P. Pacenti, Mary S. Pinkus, Jessie W. Shih, Bryan C. Tieman, Joan D. Tyner, Robert N. Ziemann, Lowell J. Tyner
-
Publication number: 20090142776Abstract: The subject of the present invention is to provide a useful antibody for measuring ADAMTS13 activity, in particular, a monoclonal antibody and a method for measuring ADAMTS13 activity. Further, another subject of the present invention also is to provide a monoclonal antibody which has specific reactivity to an antigenic determinant site produced by reacting ADAMTS13 with VWF that is a substrate or a partial peptide of VWF that is a potential substrate, but has no specific reactivity to the complete VWF molecule, and a use of the antibody of interest. Those subjects were achieved by succeeding in obtaining a monoclonal antibody (anti-N-10 monoclonal antibody) which has specific reactivity to a cleavage site that is cleavable by ADAMTS13 in the partial peptide of VWF, and further by finding a method for measuring ADAMTS13 activity using the monoclonal antibody of interest.Type: ApplicationFiled: January 26, 2006Publication date: June 4, 2009Inventors: Seiji Kato, Hisahide Hiura, Yoshihiro Fujimura, Masanori Matsumoto
-
Patent number: 7541159Abstract: Antibodies have been developed against the different molecular forms of urokinase using synthetic peptides as immunogens. The peptides were synthesized specifically to represent those regions of the urokinase molecules which are exposed in the three-dimensional configuration of the molecule and are uniquely homologous to urokinase. Antibodies are directed against the lysine 158-isoleucine 159 peptide bond which is cleaved during activation from the single-chain (ScuPA) form to the bioactive double chain (54 KDa and 33 KDa) forms of urokinase and against the lysine 135 lysine 136 bond that is cleaved in the process of removing the alpha-chain from the 54 KDa form to produce the 33 KDa form of urokinase. These antibodies enable the direct measurement of the different molecular forms of urokinase from small samples of conditioned medium harvested from cell cultures.Type: GrantFiled: April 14, 2004Date of Patent: June 2, 2009Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space AdministrationInventors: M. Zouhair Atassi, Dennis R. Morrison
-
Patent number: 7541330Abstract: A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead of inside the target cell, the cell membrane-impermeabilizing group prevents or limits entry of the modified active agent into cells, thus reducing its systemic or non-specific adverse effects, including toxicity.Type: GrantFiled: June 9, 2005Date of Patent: June 2, 2009Assignee: Kosan Biosciences IncorporatedInventors: Daniel V. Santi, Brian Hearn
-
Patent number: 7537762Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: September 6, 2006Date of Patent: May 26, 2009Assignees: Amgen Fremont, Inc., Pfizer Inc.Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelley Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Patent number: 7534433Abstract: A method for improving body weight gain and increasing feed conversion efficiency of in animals by feeding the animals a diet containing antibodies against anti-nutritional factors in food.Type: GrantFiled: June 6, 2002Date of Patent: May 19, 2009Assignee: Anitox CorporationInventor: Julio Pimentel
-
Patent number: 7524938Abstract: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.Type: GrantFiled: April 4, 2004Date of Patent: April 28, 2009Assignee: Yeda Research And Development Co., Ltd.Inventors: Irit Sagi, Tamar Danon
-
Patent number: 7524936Abstract: The present invention relates to new genes encoding for the production of novel nox enzyme proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.Type: GrantFiled: February 27, 2007Date of Patent: April 28, 2009Assignee: Emory UniversityInventors: J. David Lambeth, Guangjie Chang
-
Patent number: 7521055Abstract: Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in Xenopus oocytes. Human and mouse homologs of the ferroportin1 gene have been identified. The invention includes isolated polynucleotides, vectors and host cells comprising nucleotide sequences encoding Ferroportin1 proteins and variants thereof, including those having iron transport function. The invention also includes polypeptides encoded by ferroportin1 genes and variants of such polypeptides, and fusion polypeptides comprising a Ferroportin1 or a portion thereof.Type: GrantFiled: December 19, 2006Date of Patent: April 21, 2009Assignee: Children's Medical Center CorporationInventors: Leonard I. Zon, Adriana Donovan
-
Publication number: 20090098576Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: ApplicationFiled: October 15, 2008Publication date: April 16, 2009Applicant: IDEXX Laboratories, Inc.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis Krah, Barbara O'Brien, Marilyn Strong-Townsend
-
Patent number: 7514231Abstract: The invention concerns a monoclonal antibody directed against mammalian aurora-A kinase, the method for obtaining same, as we ll as its uses in cancer diagnosis and prognosis, and in pharmaceutical compositions for cancer treatment.Type: GrantFiled: June 12, 2003Date of Patent: April 7, 2009Assignees: Centre National de la Recherche Scientifique, Etablissement Francais du Sang-BretagneInventors: Claude Prigent, Anne Martin
-
Patent number: 7504484Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: September 29, 2006Date of Patent: March 17, 2009Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J Godowski, Austin L Gurney, William I Wood
-
Publication number: 20090068194Abstract: The present invention concerns an antibody which specifically binds to an abnormal superoxide dismutase 1 (SOD1), and which neutralizes its pathologic effect when administered to an animal such as a human. The antibody of the invention is a monoclonal antibody produced by hybridoma cell lines deposited with the International Depositary Authority of Canada on Aug. 29, 2006 under accession numbers ADI-290806-01, ADI-290806-02 and ADI-290806-03. The present invention also concerns the use of the antibody of the invention in the treatment, prevention and diagnosis of neurodegenerative diseases such as Amyotrophic lateral sclerosis, Parkinson and Alzheimer in an animal such as a human.Type: ApplicationFiled: August 31, 2006Publication date: March 12, 2009Inventors: Jean-Pierre Julien, Makoto Urushitani
-
Publication number: 20090053737Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.Type: ApplicationFiled: August 24, 2007Publication date: February 26, 2009Inventors: Boliang Cao (Brian), George F. Vande Woude, Beatrice S. Knudsen
-
Patent number: 7488808Abstract: An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.Type: GrantFiled: August 1, 2005Date of Patent: February 10, 2009Assignee: United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: John J. O'Shea, Warren J. Leonard, James A. Johnston, Sarah M. Russell, Daniel W. McVicar, Masaru Kawamura
-
Publication number: 20090022731Abstract: The invention features methods and compositions benefiting from differential gene expression observed in arthritis-associated B cells.Type: ApplicationFiled: August 16, 2007Publication date: January 22, 2009Applicant: WyethInventors: David Johannes von Schack, Matthew James Whitters, Kyriaki Dunussi-Johannopoulos, Mary Collins, Eugene Lee Brown
-
Patent number: 7473766Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding a PAK4 serine/threonine kinase. This invention provides an isolated nucleic acid molecule encoding a mutant homolog of the mammalian PAK4 serine/threonine kinase whose amino acid sequence is set forth in FIG. 1A (SEQ ID NO: 2). This invention provides a fusion protein comprising a PAK4 serine/threonine kinase or a fragment thereof and a second peptide. This invention provides a purified mammalian PAK4 serine/threonine kinase. This invention provides a protein comprising substantially the amino acid sequence set forth in FIG. 1A. This invention provides a monoclonal antibody directed to an epitope of a PAK4 serine/threonine kinase. This invention provides a method of inhibiting PAK4 function comprising administering a ligand comprising an amino acid domain which binds to a GTP binding protein so as to inhibit binding of the GTP binding protein to PAK4.Type: GrantFiled: October 24, 2003Date of Patent: January 6, 2009Assignee: The Trustees of Columbia University in the city of New YorkInventor: Audrey Minden
-
Publication number: 20080305499Abstract: The present invention relates to an antibody against synoviolin or a fragment thereof for providing a monoclonal antibody capable of recognizing a part of synoviolin, which monoclonal antibody is capable of inhibiting the auto-ubiquitination of synoviolin.Type: ApplicationFiled: July 4, 2005Publication date: December 11, 2008Applicant: Locomogene, Inc.Inventors: Toshihiro Nakajima, Satoshi Yamasaki, Lei Zhang, Tetsuya Amano
-
Publication number: 20080299584Abstract: An isolated polypeptide (JNK) characterized by having a molecular weight of 46 kD as determined by reducing SDS-PAGE, having serine and threonine kinase activity, phosphorylating the c-Jun N-terminal activation domain and polynucleotide sequences and method of detection of JNK are provided herein. JNK phosphorylates c-Jun N-terminal activation domain which affects gene expression from AP-1 sites.Type: ApplicationFiled: September 15, 2006Publication date: December 4, 2008Inventors: Michael Karin, Masahiko Hibi, Anning Lin
-
Patent number: 7452977Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I?B?, I?B? kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-?B. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.Type: GrantFiled: March 26, 2004Date of Patent: November 18, 2008Assignee: Millennium Pharmaceuticals, Inc.Inventor: Zhijian J. Chen
-
Patent number: 7439331Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: June 29, 2006Date of Patent: October 21, 2008Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20080220477Abstract: This invention relates to: a labeled amino acid that can be introduced into a protein with the aid of a protein synthesis system; a functional protein having functions derived from a label compound; a labeled amino acid comprising an aromatic ring bound to an amino acid side chain and a label compound bound thereto via the aromatic ring; a functional protein to which the labeled amino acid has been introduced; and a novel method for effectively obtaining a labeled amino acid-tRNA complex.Type: ApplicationFiled: April 22, 2008Publication date: September 11, 2008Applicants: PROTEIN EXPRESS CO., LTD., Takahiro HOHSAKAInventors: Takahiro Hohsaka, Masahiko Sisido
-
Patent number: 7423128Abstract: The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: November 3, 2004Date of Patent: September 9, 2008Assignee: Amgen Fremont Inc.Inventors: Gadi Gazit-Bornstein, Giorgio Senaldi, Xiao-Dong Yang, Bruce Keyt, Gerardo Zapata
-
Patent number: 7416853Abstract: The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds.Type: GrantFiled: November 22, 2006Date of Patent: August 26, 2008Assignee: SmithKline Beecham P.L.C.Inventors: Colin H. MacPhee, David Graham Tew
-
Publication number: 20080177046Abstract: Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) in body fluids, such as, urine and serum. Said s-CA IX comprises the extracellular domain of CA IX or portions thereof. The Predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons (kd) upon Western blot. A smaller s-CA IX form of about 20 to about 30 kd comprising the CA domain or parts thereof, not linked to the PG domain, has also been found in body fluids. Diagnostic/prognostic methods for precancer and cancer that detect or detect and quantitate said s-CA IX in body fluids, are described. Also disclosed herein is the coexpression of CA IX and HER-2/neu/c-erbB-2 that provides parallel, alternative and potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer and cancer.Type: ApplicationFiled: October 31, 2007Publication date: July 24, 2008Inventors: Jaromir Pastorek, Silvia Pastorekova, Miriam Zatovicova, Jan Zavada, Marta Ortova Gut, Zuzanna Zavadova
-
Publication number: 20080166732Abstract: The present invention relates to a novel human poly(A) polymerase enzyme (PAP), its nucleic and amino acid sequence and use thereof as well as an antibody against the novel enzyme and use thereof. The novel enzyme named PAP? and is not related to the previously known PAPs.Type: ApplicationFiled: January 31, 2008Publication date: July 10, 2008Inventors: Anders VIRTANEN, Helena Nordvarg, Christina Kyriakopolou
-
Publication number: 20080131442Abstract: IgY antibodies which specifically bind to human telomerase reverse transcriptase (hTERT) can be used to detect hTERT and thereby diagnose cancer. Preparations of the antibodies can be used to reduce hTERT reverse transcriptase activity in in vitro assays and can be used as in vivo therapeutics to treat cancer.Type: ApplicationFiled: June 26, 2006Publication date: June 5, 2008Applicant: SCIENCE APPLICATIONS INTERNATIONAL CORPORATIONInventor: Yan Xiao
-
Patent number: 7378090Abstract: Methods have been developed for alleviating memory problems or psychiatric dysfunctions that have a memory formation component. These methods are based on the finding that a truncated form of an aPKC? protein is intimately involved in memory formation in animals. This finding is also central to methods for determining drugs that will have an effect on memory formation or the memory formation component of psychiatric dysfunctions.Type: GrantFiled: April 29, 2002Date of Patent: May 27, 2008Assignees: The Research Foundation of State University of New York, Cold Spring Harbor LaboratoryInventors: Jerry C. P. Yin, Eric A. Drier, Todd C. Sacktor
-
Publication number: 20080113387Abstract: This invention relates to the detection or assessment of prion disease in an individual by determining the binding of monoclonal antibodies specific for PrP to the surface of blood cells obtained from the individual. The binding of such antibodies is shown to correlate with the progression of prion disease. Methods of detecting or assessing prion disease are provided, along with kits and reagents.Type: ApplicationFiled: January 25, 2006Publication date: May 15, 2008Applicant: Cambridge Enterprise LimitedInventors: Raymond Bujdoso, Alana Thackray
-
Patent number: 7371828Abstract: The present invention relates, in general, to an extracellular signal regulated kinase, ERK-5.Type: GrantFiled: June 16, 2003Date of Patent: May 13, 2008Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Cornelia Lechner, Niels P. Moller, Axel Ullrich
-
Patent number: 7368237Abstract: An assay uses apoptotic nucleases to screen for apoptosis modulators, in a method of modulating apoptosis, and in a method of aiding in a diagnosis of a disease, among other methods. materials for use in the assay include isolated or recombinant polypeptides and polynucleotides, compositions comprising those isolated or recombinant polypeptides and polynucleotides, vectors, transgenic organisms, and integrated systems among other aspects.Type: GrantFiled: April 23, 2004Date of Patent: May 6, 2008Inventors: Jay Parrish, Ding Xue
-
Patent number: 7361741Abstract: An antibody, or fragment thereof, capable of binding specifically to one or more human dietary enzymes, said antibody or fragment thereof comprising a heavy chain variable domain derived from an immunoglobulin naturally devoid of light chains, or a functional equivalent thereof.Type: GrantFiled: March 13, 2001Date of Patent: April 22, 2008Assignee: Lipton, division of Conopco, Inc.Inventors: Sandra Bezemer, Monique Van Der Burg, Johannes Joseph De Haard, Erwin Tareilus
-
Publication number: 20080089878Abstract: The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals.Type: ApplicationFiled: May 19, 2006Publication date: April 17, 2008Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Yonghua Zhu
-
Patent number: 7358352Abstract: The present invention provides isolated human and bovine TNF-? convertases, nucleic acids and; recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the convertases and are useful for treating medical conditions caused or mediated by TNF-?. Also provided are screening methods for identifying specific inhibitors of mammalian TNF-? convertases, and for identifying nucleic acids encoding such convertases.Type: GrantFiled: November 13, 2006Date of Patent: April 15, 2008Assignee: Schering CorporationInventors: Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A. Lunn, Jimmy C. Tan, Paul J. Zavodny
-
Patent number: 7355015Abstract: The invention is directed to a method of detecting a malignancy or a pre-malignant lesion in breast or other tissue, or a pathologic condition, by detecting the presence of single-chain or two-chain forms of matriptase in the tissue. The invention is further directed to a method of treating malignancies, which have the phenotype of matriptase production by administering a tumor formation inhibiting effective amount of concentrate of Bowman-Birk inhibitor (BBIC), or other matriptase inhibitor. The invention also is directed to nucleic acids encoding a matriptase protein or fragments thereof, and their use for structure elucidation and modeling to identify other inhibitors of matriptase, as well as to methods of identifying matriptase modulating agents, including activators and inhibitors.Type: GrantFiled: March 10, 2000Date of Patent: April 8, 2008Assignee: Georgetown University School of MedicineInventors: Robert B. Dickson, Chen-Yong Lin, Michael Johnson, Shaomeng Wang, Istvan Enyedy
-
Publication number: 20080076124Abstract: The invention relates to the nucleic acid and polypeptide sequences of one novel human PPEF-1-related gene variant (PPEF-1V). The invention also provides a process for making the polypeptides of the variant. The invention further provides a use of the nucleic acid and polypeptide sequences of the gene variant in diagnosing T-cell lymophoblastic lymphoma.Type: ApplicationFiled: September 20, 2006Publication date: March 27, 2008Applicant: Visgeneer, Inc.Inventor: Ken-Shwo Dai
-
Patent number: 7339031Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: GrantFiled: March 18, 2005Date of Patent: March 4, 2008Assignee: Merck Patent GmbHInventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
-
Publication number: 20080014598Abstract: The invention discloses ten newly discovered PI3K regulatory subunit phosphorylation sites, tyrosines 467, 452, 463, and 470 in PI3KR1 (PI3Kp85 alpha), tyrosines 464, 460, and 467 in PI3KR2 (PI3Kp85 beta), and tyrosines 199, 184, and 202 in PI3KR3 (PI3Kp55 gamma), and provides reagents, including polyclonal and monoclonal antibodies, that selectively bind to PI3K when phosphorylated at one of the disclosed sites. Also provided are assays utilizing this reagent, including methods for determining the phosphorylation of PI3K in a biological sample, selecting a patient suitable for PI3K inhibitor therapy, profiling PI3K activation in a test tissue, and identifying a compound that modulates phosphorylation of PI3K in a test tissue, by using a detectable reagent, such as the disclosed antibody, that binds to PI3K only when phosphorylated at a disclosed site. The sample or test tissue may be taken from a subject suspected of having cancer, such as lymphoma, glioma, and colon cancer, involving altered PI3K signaling.Type: ApplicationFiled: May 4, 2007Publication date: January 17, 2008Inventors: Thorsten Wiederhold, Valerie Goss, Albrecht Moritz, Klarisa Rikova, Ting-Lei Gu, Peter Hornbeck
-
Patent number: 7312321Abstract: This invention relates to newly identified polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be stimulators and/or inhibitors which are useful in therapy, to antibodies specific to such peptides, and to production of such polypeptides and polynucleotides.Type: GrantFiled: February 7, 2007Date of Patent: December 25, 2007Assignee: Solvay Pharmaceuticals B.V.Inventors: Willy Deleersnijder, Rico Wiegers, Michael Weske
-
Patent number: 7311906Abstract: Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating viral infection.Type: GrantFiled: April 28, 2005Date of Patent: December 25, 2007Assignee: Brigham Young UniversityInventors: Nathaniel Lallatin, Kim L. O'Neill
-
Patent number: 7309779Abstract: The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: June 2, 2006Date of Patent: December 18, 2007Assignee: Bristol-Myers Squibb CompanyInventors: John N. Feder, Shujian Wu, Thomas C. Nelson, Liana M. Lee